Two-page guide for advocates and activists working on the engagement of key population-led groups in the implementation planning of PEPFAR’s Key Population Investment Fund (KPIF). Includes information on the fund, KPIF countries, lead agencies in each country, activist demands and to-do list.
An Activist’s Guide to Influencing and Monitoring KPIF Rollout
One Timeline, Two Stories, One Message: Putting trials and targets together
One problem with HIV prevention agendas is that they either live in an eternal present or in a far-off future. It’s “work with what we’ve got, which is condoms and VMMC and a little bit of PrEP”, or it’s “nothing can change without an AIDS vaccine”. The future depends on using what’s available, better and more widely, without ever losing sight of what’s in the pipeline.
As the figures below show, in the very same timeframe that the world will miss its critical target for incidence reduction and scale-up of primary prevention, several trials will release results that could change the future. 2020 will be a time of hope and reckoning. But only if the two stories start to be told as one.
Contraception and HIV Prevention: A clear picture of women’s needs
Women face many choices about HIV prevention and contraception. Funders and governments need to move to integrated programs that provide a variety of services in one place.
Peers are Primary: Towards a systematic approach to lay cadres
Across Treatment U=U and prevention programs, peer navigators, mentor mothers and lay counselors are recognized as essential to good services. Yet many countries don’t have clear schemas for quantifying the number of individuals needed, budgeting for their remuneration and defining the roles and responsibilities that lead to impact. Activists are working to ensure clarity by demanding from governments, funders and implementers.
Towards a Demand Creation Cascade
Many countries report low initiation and continuation of PrEP. This doesn’t mean people don’t want the product. They might not want the program that’s offering it; or they might not be being reached. A “demand-creation cascade” such as the one proposed here for PrEP is one way to evaluate the program and the product. It would measure how many people received the full suite of demand-side activities the program hopes to deliver at a given stage. The precise set of steps would depend on the service-delivery design and strategy in question.
Phases of Informed-Choice PrEP Counseling
This flow chart emerged from socio-behavioral research, including surveys and in-depth interviews with Kenyan and South African women. The research team set out with the goal of adapting the informed-choice approach used in family planning programs for use in PrEP, a prime example of fields learning from each other. The result is very clinic-centered; AVAC has added the column at the far right to reflect additional elements. However, it is a step towards much-needed exploration of how to make informed choice a reality in HIV prevention today.
Putting Women at the Center: Informed choice in 2018 and beyond
We need to give women the choice to use DTG or not and to use contraception if indicated and desired. We need to support choices across options, with risk reduction—not use of a specific product—as the primary outcome. We need to give women the choice to use DMPA-IM or –SC or not, and to use HIV prevention as desired.
AVAC Report 2018: No Prevention, No End!
AVAC’s 2018 annual state of the field report, No Prevention, No End! looks at today’s prevention crisis and offers context, analysis and strategy to turn that crisis around.
Oral PrEP Enrollment Snapshot
For trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot. This PowerPoint deck illustrates major findings from the tracker with heat maps showing where people are initiating PrEP, updates against targets and more. A PDF version is also available.
HIV Vaccine Science, Research, Updates and Advocacy
With HIV Vaccine Awareness Day (HVAD) in the spotlight earlier this month, AVAC’s May episode of PxPulse features four experts steeped in HIV vaccine research. Together they help set expectations for where the field is now and where it is going.